Phenotypic screening using iPSC-based human disease biology

Supported by:

27 March 2019

Supported by:

27 March 2019

Phenotypic screening using iPSC-based human disease biology

  • iPSC-derived human disease models that can be scaled to support HTS efficacy campaigns through robust bioprocessing/manufacturing
  • Walk through a case study that demonstrates efficient iPSC-derived cardiomyocyte scale up, HTS assay development/validation, and a phenotypic HTS campaign of over 3,600 compounds from Ncardia’s “smart library”

Ncardia discussed the application of human iPSC-derived cell-based assays and high throughput screening for drug discovery and development. This approach enables researchers to access human disease-relevant biology earlier in the drug discovery process. They will explore a phenotypic drug screening platform composed of genetic and induced human iPSC-derived cardiac and neural disease models, controlled bioreactor-based manufacturing to enable batch sizes compatible with high-throughput screening (HTS), generation and validation of disease-relevant assays with clinically relevant readouts, and high-throughput screening using qualified disease assays.


Register to watch this on-demand webinar

    Unless making a secure payment with your credit or debit card via a third-party payment processor, this form is not designed to collect confidential or sensitive personal information (e.g., financial information, social security numbers).

    *Required field

    Your details

    Email preferences

    If you’re not already opted-in to receive our emails, please select which types of communication you would like to receive:

    Confirm that you're human

    By clicking register, you consent to Drug Target Review contacting you about this and future webinars, and that you agree to our terms and conditions and privacy policy. Your information will be processed in accordance with GDPR and you can unsubscribe at any time.


    Greg Luerman, PhDGreg Luerman, PhD, Technical Director at Ncardia

    Greg Luerman (PhD) is Technical Director at Ncardia. Following his graduate studies at the University of Louisville School of Medicine, Dr. Luerman earned a Michael J Fox Foundation postdoctoral fellowship within the Pfizer Neuroscience Research Unit where he lead bioassay development on a Parkinson’s disease therapeutic team. He moved on to establish a preclinical cardiac safety/tox and drug discovery assays at ChanTest (now Charles River). Now at Ncardia, Dr. Luerman oversees North American scientific operations.

    Farbod FamiliFarbod Famili, Sr.Scientist, Assay development & High throughput at Ncardia

    Farbod Famili (PhD) is Scientific Lead of assay development and high-throughput compound screening projects at Ncardia. His responsibilities include development and validation of assays in various cardiovascular cellular disease models using proprietary hiPSC-derived cardiomyocytes, high-throughput compound screening and target identification. Farbod has also developed expertise in application on of robotic liquid handling systems in 384 and 1536-well microplates.